# MOCK – DCRI Master Services Agreement: BlueFern Biologics (Phase III Global Support)

This is a MOCK sample for tooling tests. No real data.

Parties: Duke Clinical Research Institute (DCRI) and BlueFern Biologics Ltd.

Effective Date: November 5, 2025

Scope: Global site management, central monitoring, stats/programming for BF‑112 Phase III.

Budget Summary (Proposed): Fixed Fee: $6,250,000; Pass‑through Management: 12%; Close‑out: $750,000.

Fixed Fee (proposed): $6,250,000 (floor: $5,500,000).

Pass‑through Management Fee: 12% (minimum: 10%).

Monitoring Visit Interval: Every 8 weeks

IP Clause: Sponsor owns study‑specific deliverables; DCRI retains platform IP and know‑how

Publication & Authorship: ICMJE criteria apply; minimum acknowledgment for non‑author DCRI analysts.